Molecular profiling has revealed multiple overlapping pathways driving GBM progression—including EGFR amplification/mutation, alterations in TP53, PTEN loss, and activation of PI3K/AKT signaling—that not only drive tumorigenesis but also shape antigenic landscapes and mechanisms of immune evasion. The gene discussed is EGFR; the disease is glioblastoma.